Site and Mechanism(s) of Expiratory Airflow Limitation in COPD, Emphysema and Asthma-COPD Overlap
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age30+
SponsorGelb, Arthur F., M.D.
About this trial
The purpose of this cross-sectional, observational study is to evaluate the site and mechanism(s) for expiratory airflow limitation in chronic, treated, current or former smokers (\>15 pack years) with COPD, Emphysema, and Asthma-COPD Overlap with mild to severe expiratory airflow limitation. Treatment may include short and long acting inhaled beta2agonists, short and long acting inhaled muscarinic receptor antagonists, inhaled and or oral corticosteroid, oral antibiotic, supplemental oxygen, and PDE type 4 inhibitor. In some cases, the patient may have had a history of asthma preceding the development of COPD (Asthma COPD Overlap).
Eligibility criteria
This trial accepts healthy volunteersQualifiers
asthma- copd overlap
emphysema in smokers with smoking history > 15 pack years
COPD/ bronchitis and bronchiectasis in smokers with smoking history
>15 pack years
Disqualifiers
non smokers
any other pulmonary diagnosis
pulmonary fibrosis
Trial population
As above
Trial design
Design model
Case-only
Time perspective
Cross-sectional
Treatments tested in this trial
As above: diagnosis: COPD, Emphysema, Asthma-COPD Overlap
Other intervention
Treatment groups
60 Participants
are divided into 1 treatment groupGroup A: COPD, Emphysema, Asthma-COPD Overlap1 intervention
Trial outcomes
Primary outcomes
1
Site and Mechanism(s) of Expiratory Airflow Limitation
Contribution of loss of lung lastic recoil vs intrinsic airway obstruction
Time frame
4 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov